Recent News

• 04.25.2025 - Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
• 04.23.2025 - Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
• 04.15.2025 - Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
• 03.26.2025 - DKN-01 DeFianCe Data Update
• 03.26.2025 - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.26.2025 - Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
• 01.28.2025 - DKN-01 DeFianCe and DisTinGuish Data Update - Q1 2025

Recent Filings

• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2025 - S-8 Securities to be offered to employees in employee benefit plans